Acute Ischemic StrokeNCT04571177
PET Perfusion Imaging Techniques and Comparing Them to CT Perfusion Imaging in Stroke
An observational study of Acute Ischemic Stroke, run by University of Alberta at 1 site in Canada.
Trial summary
Adult patients who are diagnosed with an acute supratentorial ischemic stroke within 48 hrs of onset will be enrolled into the study. Participants will undergo both a CT Scan and PET scan within 7 days of onset. Participants will have the option to undergo a second PET scan with fluorodeoxyglucose (FDG). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Ischemic Stroke
- How many people
- 20 participants
- Where
- 1 siteCanada
- Study dates
- 1 Feb 2016to 31 Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who are older than 18 years of age diagnosed with an acute supratentorial ischemic stroke within 48 hrs of onset will be enrolled into the study. Both male and female patients will be enrolled. We want diversity among participants in order to gain insightful information about acute supratentorial ischemic stroke as possible. A broad range in age, along with enrolling both male and female participants will allow greater diversity.
Who may be able to join
- Age: >18 yo
- Gender: male or female
- Acute (within 7 days from symptom onset) Supratentorial Ischemic Stroke
Who cannot join
- 1) Planned surgical intervention
- 2) Severely abnormal blood glucose level (will be excluded from FDG PET imaging)
- 3) Unable to undergo CTP or PET imaging (i.e. claustrophobia)
- 4) Pregnancy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Developing PET Perfusion Imaging Techniques and Comparing Them to CT Perfusion Imaging in Stroke Patients
Adult patients who are diagnosed with an acute supratentorial ischemic stroke within 48 hrs of onset will be enrolled into the study. Participants will undergo both a CT Scan and PET scan within 7 days of onset. Participants will have the option to undergo a second PET scan with fluorodeoxyglucose (FDG).
Read the detailed description
Patients older than 18 years of age diagnosed with an acute supratentorial ischemic stroke within 48 hrs of symptom onset will be prospectively enrolled. Research imaging will be obtained before 7 days after symptom onset. The patient will receive the standardized treatment protocol at the hospital. Informed consent will be obtained from each patient or a substitute decision maker for each individual imaging study (CTP, Rb PET, and FDG PET). The patient will be given the option of undergoing the CTP imaging with the Rb PET only or both the Rb PET and FDG PET components.
- Conditions
- Acute Ischemic Stroke
- Medical subject headings
- Ischemic Stroke
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare PET brain perfusion imaging to CTP
Imaging of CTP images with the Rb PET only or both the Rb PET and FDG PET with CTP imaging components to evaluate blood flow and metabolism mismatches.
Measured: through study completion, 1 year from start of recruitment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2020
- Study start1 Feb 2016
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Ischemic StrokeStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Brian Buck, Principal investigator, Associate Professor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04571177
- Sponsor's protocol ID
- Version 1.0 28AUG2019
- Status last verified
- Apr 2026
- First submitted
- 19 May 2020
- Last updated
- 13 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Developing PET Perfusion Imaging Techniques and Comparing Them to CT Perfusion Imaging in Stroke Patients
- ClinicalTrials.gov ID
- NCT04571177
- Acronym / sponsor ID
- Version 1.0 28AUG2019
- Conditions
- Acute Ischemic Stroke
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Study start
- 1 Feb 2016 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 30 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adult patients who are diagnosed with an acute supratentorial ischemic stroke within 48 hrs of onset will be enrolled into the study. Participants will undergo both a CT Scan and PET scan within 7 days of onset. Participants will have the option to undergo a second PET scan with fluorodeoxyglucose (FDG).
Detailed description
Patients older than 18 years of age diagnosed with an acute supratentorial ischemic stroke within 48 hrs of symptom onset will be prospectively enrolled. Research imaging will be obtained before 7 days after symptom onset. The patient will receive the standardized treatment protocol at the hospital. Informed consent will be obtained from each patient or a substitute decision maker for each individual imaging study (CTP, Rb PET, and FDG PET). The patient will be given the option of undergoing the CTP imaging with the Rb PET only or both the Rb PET and FDG PET components.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who are older than 18 years of age diagnosed with an acute supratentorial ischemic stroke within 48 hrs of onset will be enrolled into the study. Both male and female patients will be enrolled. We want diversity among participants in order to gain insightful information about acute supratentorial ischemic stroke as possible. A broad range in age, along with enrolling both male and female participants will allow greater diversity.
Key inclusion criteria (3 listed)
- Age: >18 yo
- Gender: male or female
- Acute (within 7 days from symptom onset) Supratentorial Ischemic Stroke
Key exclusion criteria (4 listed)
- 1) Planned surgical intervention
- 2) Severely abnormal blood glucose level (will be excluded from FDG PET imaging)
- 3) Unable to undergo CTP or PET imaging (i.e. claustrophobia)
- 4) Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Compare PET brain perfusion imaging to CTP
Time frame: through study completion, 1 year from start of recruitment
Imaging of CTP images with the Rb PET only or both the Rb PET and FDG PET with CTP imaging components to evaluate blood flow and metabolism mismatches.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Ischemic Stroke
Not yet recruitingPhase 3
Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
Ischemia Stroke, TIA (Transient Ischemic Attack)
Not yet recruitingPhase 3
INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Stroke, Acute Ischemic, Medium Vessel Occlusion
Active, not recruitingPhase 4
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
Ischemic Stroke Hospitalized, Impairment, Cognitive
Not yet recruitingPhase 4
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
Ischemic Stroke
Recruiting
Connectomic Alterations Following Acute Ischemic Stroke in the MCA Territory
Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Brian Buck principal investigator
Associate Professor
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Ischemic Stroke, run by University of Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare PET brain perfusion imaging to CTP (time frame: through study completion, 1 year from start of recruitment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.